Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02506751 · ClinicalTrials.gov registry record · Phase 1
Open-label Study of Liothyronine in MS
A Phase 1 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT02506751: Completed Phase 1 study, sponsored by Johns Hopkins University.
NCT02506751 is a Phase 1 study that has completed, run by Johns Hopkins University. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02506751, a Phase 1 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of synthetic T3, liothyronine. It will establish if there are changes in MS symptoms and if there is a positive effect on markers of neuronal health.
Interventions
- DRUG liothyronine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-07 |
| Est. Completion | 2017-09-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02506751
The ClinicalTrials.gov registry entry for NCT02506751 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which liothyronine is the first listed.
NCT02506751 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02506751 about?
NCT02506751 is a clinical study titled "Open-label Study of Liothyronine in MS". This study will evaluate the safety and tolerability of synthetic T3, liothyronine. It will establish if there are changes in MS symptoms and if there is a positive effect on markers of neuronal health.
What is the current status of trial NCT02506751?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2015-07. Estimated completion is 2017-09-18.
What interventions are being tested in trial NCT02506751?
The interventions under investigation include: liothyronine (DRUG).
Who is sponsoring clinical trial NCT02506751?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.